Trading Signals: INO Stock Price Prediction and Forecast (Tue. Apr. 1, 2003 - Fri. Jan. 15, 2021)(Inovio Pharmaceuticals, Inc. )
| INO latest price $10.2100 (2.1%) ($9.8600 - $10.2700) on Tue. Nov. 3, 2020. | |
| | Trend Analysis and Forecast | | | Trend Pattern | Growing Downtrend | Trend Narrative | Downtrend | Average Daily Price Swing | $0.91 (8.06% one month average) | Average Daily Percentage Swing | 8.52% (three month average) | Weekly Trend Force | -0.8% (StdDev 8.52%) | Daily Moving Force | -0.6% | Rebound Strength | None(0%) | Trend | -1.08% | Latest Price | $10.2100(2.1%) | Forecasted Low Price | 9.85(-3.5%) | Forecasted High Price | 10.42(2.1%) | Direction of Next Movement | Lower(-4.9%) | % Change Needed to Confirm Rebound | 2.5% ((10.47)) | % Change Needed for Trend Reversal | 7.7% | Hourly Trend | 0.5% [$10.08(0.05), $10.21(-0.16)] | Stocks Behave Similarly | Similar Stock List | Complacency | 2 | Intraday Reversal Probability | There's a high probability the price will reverse sharply to upside intraday or next day.. | Daily Trend | INO declines -1.7% a day on average for past five trading days. | Weekly Trend | INO declines -6.2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support INO decline at-0.7% a week (31% probability) XBI(41%) IBB(30%) ARKG(28%) GLD(25%) ARKK(23%) | Factors Impacting INO price | INO will decline at least -2.8% in a week (12% probabilities). JETS(-15%) VXX(-12%) EWJ(-12%) XLF(-9%) EWI(-6%) | Explanation | The decline is sustainable and supported by the broad market. | Trading Plan | Not Available | | | Valuation to SPY | -1.4 | | | Relative Volatility | -1.1 (options are cheap) | | | Market Trend Strength | -4.3% (StdDev 8.52%) | Hourly BBV | -3 () | Intraday Trend | 0% | | | |
|
Next Day Open Price | $10.27(0.6%) | 1 - 5 Day Possible Target | $8.93(-12.54%) | Resistance Level | $11.29 | 5 Day Moving Average | $10.31(-0.97%) | 10 Day Moving Average | $10.56(-3.31%) | 20 Day Moving Average | $11.29(-9.57%) | To recent high | -53.1% | To recent low | 6.6% | Market Cap | $1.621b | | Option Sentiment | | | | Earning Release Date | Wed. Mar. 17, 2021 | Analyst One Year Target Price | $13.71 ($8.00 - $25.00) 7 analysts (last updated on Sun. Oct. 25, 2020) | % to Average Target Price | 34.28% | % to Low Target Price | -21.65% | % to High Target Price | 144.86% | | |
Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The firm's drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
June 23 announcement that it had received $71 million from the U.S. Department of Defense (DoD) pertaining to its two Cellectra devices, both of which are used to administer its COVID-19 vaccine candidShares fell sharply in the two-day period following the company's June 30 announcement of interim phase 1 poisitive results for its COVID-19 vaccine candidate. Inovio plans to begin a phase 2/3 clinical study for INO-4800 this summer assuming it receives the FDA's approval.ate INO-4800. |